New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareOrforglipron vs Alpha-GPC

Orforglipron vs Alpha-GPC

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss Agonists
Orforglipron
Cognitive Enhancement
Alpha-GPC
Summary
Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
Alpha-GPC is the most bioavailable form of choline, readily crossing the blood-brain barrier to rapidly increase acetylcholine levels. It enhances cognitive performance, supports GH secretion, and is used as an essential complement to many nootropic peptides (especially those that increase acetylcholine demand like Noopept and Dihexa).
Half-Life
~12 hours (once-daily oral dosing)
~4–6 hours
Admin Route
Oral
Oral, SubQ
Research
Typical Dose
12 mg → 24 mg → 36 mg → 45 mg
300–600 mg
Frequency
Once daily
1–2x daily
Key Benefits
  • Oral pill — no injections required
  • Once-daily dosing without food restrictions (unlike oral semaglutide)
  • Up to 9.4% body weight reduction in Phase 2 at 36 weeks
  • Significant HbA1c reduction in type 2 diabetes trials
  • Small-molecule stability — no cold chain requirements
  • Broadens access for injection-averse patients
  • Potential class-defining convenience advantage over injectable GLP-1s
  • Rapidly raises brain acetylcholine levels
  • Enhances memory formation and recall
  • Prevents headaches from nootropic peptides (choline donor)
  • Stimulates growth hormone secretion (modest)
  • Improves attention and processing speed
  • Neuroprotective in Alzheimer's and cognitive decline
  • Approved in Europe for Alzheimer's therapy
  • Enhances power output in athletes (pre-workout)
Side Effects
  • Nausea (most common, dose-dependent)
  • Vomiting
  • Diarrhea
  • Decreased appetite
  • +2 more
  • Headache (paradoxically, from excess acetylcholine at very high doses)
  • Nausea at doses > 1200 mg
  • Dizziness
  • Fatigue at high doses
  • +1 more
Stacks With